Itraconazole was a dual-profile compound, which showed agonistic activity with EC50 of 200 nM on ERα but a higher antagonistic activity with IC50 of 280 nM on ERβ than tamoxifen, a classical anti-breast cancer drug. Here, ESR1 is linked to breast cancer.